Predict your next investment

GT Medical Technologies company logo
HEALTHCARE | Medical Devices & Equipment / Device Design & Manufacturing
gtmedtech.com

See what CB Insights has to offer

Founded Year

2017

Stage

Series B | Alive

Total Raised

$28.45M

Last Raised

$16M | 10 mos ago

About GT Medical Technologies

GT Medical Technologies focuses on improving the lives of patients with brain tumors. The company created the GammaTile, a device that has shown to be effective in treating tumors that recurred after conventional therapy.

GT Medical Technologies Headquarter Location

1809 S. Holbrook Lane Suite 107

Tempe, Arizona, 85281,

United States

Latest GT Medical Technologies News

GT Medical Technologies Presents Clinical Data on GammaTile® Therapy for Brain Tumors at the 2021 American Association of Neurological Surgeons Scientific Virtual Meeting

Aug 24, 2021

New Data Details How Surgically Targeted Radiation Therapy (STaRT) Provides One-and-Done Radiation Treatment at the Time of Brain Tumor Removal News provided by Share this article Share this article TEMPE, Ariz., Aug. 24, 2021  /PRNewswire/ -- GT Medical Technologies, Inc.  today announced it is presenting clinical data in two oral presentations on the company's breakthrough GammaTile® Therapy for patients with brain tumors at the 2021 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting. The presenting authors, Dr. David Brachman, co-founder and CTO at GT Medical Technologies and Dr. Mehee Choi, director of Medical Affairs at GT Medical Technologies, will discuss new data in patients with recurrent glioblastoma (GBM), and access-to-care for patients with resectable brain tumors. GammaTile is an implantable radiation therapy consisting of bioresorbable collagen tiles embedded with Cesium-131 sources provided by Isoray, Inc. It is the first medical device cleared for brain tumor treatment in the U.S. in the last ten years. "GammaTile Therapy improves the lives of patients with newly diagnosed malignant and recurrent brain tumors," said Matthew Likens, president and CEO of GT Medical Technologies, Inc. "Data presented at AANS highlights clinical efficacy of the therapy, but also important access-to-care and quality-of-life benefits that GammaTile provides these patients. It's the first device of its kind, and its ability to deliver safe and effective Surgically Targeted Radiation Therapy (STaRT) for patients is groundbreaking in the neuro-oncology community." The in-person AANS meeting was cancelled due to Covid-19. As the pandemic disrupts travel and events, it is vital to remember that cancer treatment is not elective. GammaTile is a one-and-done radiation option for patients with brain tumors that eliminates the need for daily, ongoing radiation treatments. Patients receive ongoing, therapeutic radiation from the safety of their own home, protecting them from unnecessary exposure to Covid-19, and delivering life-extending treatment. This and other access to care benefits will be featured in the abstracts presented at AANS. Register today here  and watch the following oral presentations online: "Resection and Surgically Targeted Radiation Therapy (STaRT) for treatment of recurrent GBM," presenting author: David Brachman, MD, Radiation Oncologist, GT Medical Technologies, Inc. "Access to specialty radiotherapy care for patients with resectable brain tumors," presenting author: Mehee Choi, MD, Radiation Oncologist, GT Medical Technologies, Inc. In addition to the abstracts presented at the AANS Annual Scientific Meeting, GammaTile Therapy was featured in two scientific abstracts at the 2021 Society of Neuro-Oncology (SNO) Conference on Brain Metastases last week. Read the following abstracts online: About GT Medical Technologies, Inc. Driven to overcome the limitations of current treatments for brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with the purpose of improving the lives of patients with brain tumors. Its GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors and newly diagnosed malignant tumors. Patients receive their course of radiation while going about their daily lives, requiring no additional trips to the hospital or clinic for radiation therapy. GammaTile is available in top brain tumor centers across the United States. For more information or to find a GammaTile center near you, visit  https://www.gtmedtech.com/  and follow @GTMedTech  on Twitter and LinkedIn . SOURCE GT Medical Technologies

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GT Medical Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GT Medical Technologies is included in 3 Expert Collections, including Neuroscience.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

M

Medical Devices

10,410 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. Excludes CDMOs/CMOs. *Columns updated as regularly as possible.

C

Cancer

3,592 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

GT Medical Technologies Patents

GT Medical Technologies has filed 11 patents.

The 3 most popular patent topics include:

  • Radiation therapy
  • Medical physics
  • Radiobiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/14/2019

4/20/2021

Radiation therapy, Oncology, Experimental cancer drugs, Monoclonal antibodies, Medical physics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/14/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

4/20/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Radiation therapy, Oncology, Experimental cancer drugs, Monoclonal antibodies, Medical physics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

GT Medical Technologies Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

GT Medical Technologies Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.